WallStreetZenWallStreetZen

NASDAQ: QUIT
Achieve Life Sciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for QUIT

Based on 3 analysts offering 12 month price targets for Achieve Life Sciences Inc

Min Forecast
$12.00+86.05%
Avg Forecast
$14.33+122.22%
Max Forecast
$18.00+179.07%

Should I buy or sell QUIT stock?

Based on 3 analysts offering ratings for Achieve Life Sciences Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although QUIT's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates QUIT as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their QUIT stock forecasts and price targets.

QUIT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-30
lockedlocked$00.00+00.00%2026-08-13
lockedlocked$00.00+00.00%2026-06-22

1 of 1

Forecast return on equity

Is QUIT forecast to generate an efficient return?

Company
72.35%
Industry
18.67%
Market
160.87%
QUIT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is QUIT forecast to generate an efficient return on assets?

Company
63.34%
Industry
19.68%
QUIT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

QUIT earnings per share forecast

What is QUIT's earnings per share in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
-$1.41
Avg 2 year Forecast
-$0.69
Avg 3 year Forecast
$0.11

QUIT revenue forecast

What is QUIT's revenue in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$36.1M
Avg 3 year Forecast
$137.0M

QUIT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
QUIT$6.45$14.33+122.22%Strong Buy
SGMT$11.41$26.46+131.94%Buy
KURA$7.73$30.67+296.73%Strong Buy
CADL$9.22$22.00+138.61%Strong Buy
ZVRA$11.85$26.88+126.79%Strong Buy
View Top Biotech Stocks

Achieve Life Sciences Stock Forecast FAQ

Is Achieve Life Sciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: QUIT) stock is to Strong Buy QUIT stock.

Out of 3 analysts, 2 (66.67%) are recommending QUIT as a Strong Buy, 1 (33.33%) are recommending QUIT as a Buy, 0 (0%) are recommending QUIT as a Hold, 0 (0%) are recommending QUIT as a Sell, and 0 (0%) are recommending QUIT as a Strong Sell.

If you're new to stock investing, here's how to buy Achieve Life Sciences stock.

What is QUIT's earnings growth forecast for 2026-2028?

(NASDAQ: QUIT) Achieve Life Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.69%.

Achieve Life Sciences's earnings in 2026 is -$111,709,000.On average, 15 Wall Street analysts forecast QUIT's earnings for 2026 to be -$154,851,491, with the lowest QUIT earnings forecast at -$200,570,808, and the highest QUIT earnings forecast at -$72,787,793. On average, 15 Wall Street analysts forecast QUIT's earnings for 2027 to be -$76,044,813, with the lowest QUIT earnings forecast at -$128,322,184, and the highest QUIT earnings forecast at -$23,107,236.

In 2028, QUIT is forecast to generate $11,718,670 in earnings, with the lowest earnings forecast at -$45,290,183 and the highest earnings forecast at $138,643,416.

What is QUIT's revenue growth forecast for 2026-2028?

(NASDAQ: QUIT) Achieve Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.33%.

Achieve Life Sciences's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast QUIT's revenue for 2026 to be $0, with the lowest QUIT revenue forecast at $0, and the highest QUIT revenue forecast at $0. On average, 15 Wall Street analysts forecast QUIT's revenue for 2027 to be $3,975,654,966, with the lowest QUIT revenue forecast at $647,002,607, and the highest QUIT revenue forecast at $13,769,711,949.

In 2028, QUIT is forecast to generate $15,072,519,920 in revenue, with the lowest revenue forecast at $5,337,771,509 and the highest revenue forecast at $35,639,060,278.

What is QUIT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: QUIT) forecast ROA is 63.34%, which is higher than the forecast US Biotechnology industry average of 19.68%.

What is QUIT's Price Target?

According to 3 Wall Street analysts that have issued a 1 year QUIT price target, the average QUIT price target is $14.33, with the highest QUIT stock price forecast at $18.00 and the lowest QUIT stock price forecast at $12.00.

On average, Wall Street analysts predict that Achieve Life Sciences's share price could reach $14.33 by Sep 30, 2027. The average Achieve Life Sciences stock price prediction forecasts a potential upside of 122.22% from the current QUIT share price of $6.45.

What is QUIT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: QUIT) Achieve Life Sciences's current Earnings Per Share (EPS) is -$1.36. On average, analysts forecast that QUIT's EPS will be -$1.41 for 2026, with the lowest EPS forecast at -$1.82, and the highest EPS forecast at -$0.66. On average, analysts forecast that QUIT's EPS will be -$0.69 for 2027, with the lowest EPS forecast at -$1.17, and the highest EPS forecast at -$0.21. In 2028, QUIT's EPS is forecast to hit $0.11 (min: -$0.41, max: $1.26).

What is QUIT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: QUIT) forecast ROE is 72.35%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.